Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • ROOMS:

Congress Requests Probe Of FDA Rejection Of Dendreon's Provenge

Several members of Congress questioned the FDA's review of Dendreon Corp.'s (Nasdaq: DNDN) prostate cancer treatment Provenge saying that two panel advisors had financial ties to Dendreon rivals. An investigation into the panel's rejection Provenge was requested sending shares of the biotechnology firm soaring $1.34 to close at $6.98.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.